Medical Xpress August 8, 2024
Steven Lee, University of Texas Health Science Center at San Antonio

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio).

The window trial, in which patients agreed to receive a novel treatment before undergoing surgery, found that the drug sacituzumab govitecan was well-tolerated and showed signs of effectiveness for those whose had progressed to brain tumors.

About half of all women with the aggressive and advanced triple-negative form of breast cancer will be diagnosed with brain metastases, and the prognosis is poor, with a of just more than seven months.

“We...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
How Americans feel about weight-loss drugs, in 3 charts
Tariffs on China threaten could drive up drug costs, exacerbate shortages: 5 notes

Share This Article